How Statistical Modeling and Simulation is Supporting Drug Development

This event is now available on demand.

Event overview

Drug development processes become more efficient, in terms of time and cost, with the assistance of modeling and simulation approaches widely utilized and accepted in the pharmaceutical industry. In addition, they are highly supported by regulators.

This presentation provides decision makers with an overview as to “why” modeling and simulation is important in the drug development industry. Several real-world examples that address the “what” approaches and explain “how” these approaches should be conducted to enhance the drug development process will be highlighted during the webinar.

Three key take-aways

Learn more about:

Utilizing modeling and simulation approaches to enhance drug development efficiency (eg, increase success rates and save time and money).
Wide applicability and regulator support of modeling and simulation approaches in the drug development industry.
Capabilities of the IQVIA modeling team to provide relevant modeling services.

For any technical questions please contact Jordan Ramesh: jramesh@mjhlifesciences.com

Zheng Liu, PhD
Director, Quantitative Clinical Pharmacology
IQVIA

Dr. Liu leads the PK/PD modeling team at IQVIA. He was trained as a mathematic modeling specialist, for which he holds a PhD, and has more than 10 years’ experience in PK/PD modeling field. Before he joined IQVIA in 2020, Dr Liu worked in Certara as a modeling consultant. In addition, he worked as a modeling expert for several institutes, including Melbourne Royal Children’s Hospital, University of Newcastle in Australia, Otago University in the New Zealand, and the International Atomic Energy Agency.

Please complete this form to register for the webcast. (* indicates required field)

How Statistical Modeling and Simulation is Supporting Drug Development

Please complete this form to register for the webcast.
(* indicates required field)